Dr. Arden Barry shares his team's findings from their large population database when evaluating the effect of exposure to P2Y12 inhibitors, versus no exposure, on the occurrence of major adverse cardiovascular events. The results support the use of P2Y12 inhibitors (primarily clopidogrel), in addition to other standard cardiovascular preventive therapy, in patients who undergo CABG surgery, but take a listen for all the details. Access the OPEN ACCESS manuscript here: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.70047